Cardioprotective Effects of Melatonin in Patients With Cardiomyopathy

Launched by TANTA UNIVERSITY · Feb 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of melatonin, a natural hormone, on patients who have cardiomyopathy, a condition that affects the heart muscle and can lead to heart problems. The goal is to see if melatonin can help protect the heart in these patients. The trial is currently recruiting participants aged 65 to 74 years, and both men and women can take part.

To be eligible for this study, you need to be an adult with a confirmed diagnosis of cardiomyopathy and be stable on standard heart medications, like ACE inhibitors or beta-blockers. It's important that you haven't been hospitalized for worsening heart issues recently or have serious kidney or liver problems. Participants will need to provide consent to join the study and may be asked to avoid other medications that could interfere with the results. If you join the trial, you can expect to receive careful monitoring and support throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (≥18 years) with a confirmed diagnosis of cardiomyopathy based on clinical, echocardiographic, or imaging findings. .
• • Stable condition on standard cardiomyopathy medications (e.g., ACE inhibitors, beta-blockers).
• • Ability to provide informed consent.
• Exclusion Criteria:
• • Recent hospitalization for cardiomyopathy exacerbation (within the last 3 months).
• • Severe kidney or liver impairment.
• • Use of other investigational drugs or antioxidants.
• • Pregnancy or planning to be pregnant in the next 6 months
• • Previous known hypersensitivity to melatonin.
• • Presence of atrial fibrillation or other significant arrhythmias at baseline.
• • Participation in another research.